Nutritional regulation of extrarenal vitamin D hydroxylase expression - Potential application in tumor prevention and therapy

Future Oncology

Volumn 1, Issue 3, 2005, Pages 415-424

  Cross, Heide S ^a   Kállay, Enikö ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

25 hydroxyvitamin D3 1; 25 hydroxyvitamin D3 24 hydroxylase (CYP24); epigenetics; extrarenal calcitriol synthesis and catabolism; folate intake; nutritional calcium; phytoestrogens, sporadic colorectal cancer; prostate cancer; vitamin D insufficiency

Indexed keywords

CYTOCHROME P450; STEROID MONOOXYGENASE; VITAMIN D; VITAMIN D 24 HYDROXYLASE; VITAMIN D 24-HYDROXYLASE;

ANIMAL; COLON TUMOR; DIET SUPPLEMENTATION; ENZYMOLOGY; GENE EXPRESSION REGULATION; HUMAN; MALE; METABOLISM; PROSTATE TUMOR; REVIEW;

ANIMALS; COLONIC NEOPLASMS; CYTOCHROME P-450 ENZYME SYSTEM; DIETARY SUPPLEMENTS; GENE EXPRESSION REGULATION; HUMANS; MALE; PROSTATIC NEOPLASMS; STEROID HYDROXYLASES; VITAMIN D;

EID: 33646460311     PISSN: 14796694     EISSN: 17448301     Source Type: Journal    
DOI: 10.1517/14796694.1.3.415     Document Type: Review

References (48)

1. Garland CF, Garland FC: Do sunlight and vitamin D reduce the likelihood of colon cancer? Int. J. Epidemiol. 9, 227-231 (1980).
2. Nesby-O'Dell S, Scanlon KS, Cogswell ME et al.: Hypovitaminosis D prevalence and determinants among African American and white women of reproductive age: third National Health and Nutrition Examination Survey, 1988-1994. Am. J. Clin. Nutr. 76, 187-192 (2002).
3. Grant WB: An estimate of premature cancer mortality in the US due to inadequate doses of solar ultraviolet-B radiation. Cancer 94, 1867-1875 (2002).
4. Kudlacek S, Schneider B, Peterlik M et al.: Assessment of vitamin D and calcium status in healthy adult Austrians. Eur. J. Clin. Invest. 33, 323-331 (2003).
5. Tangpricha V, Pearce EN, Chen TC, Holick MF: Vitamin D insufficiency among freeliving healthy young adults. Am. J. Med. 112, 659-662 (2002).
6. Holt PR, Arber N, Halmos B et al.: Colonic epithelial cell proliferation decreases with increasing levels of serum 25-hydroxy vitamin D. Cancer Epidemiol. Biomarkers Prev. 11, 113-119 (2002).
7. Tuohimaa P, Tenkanen L, Ahonen M et al.: Both high and low levels of blood vitamin D are associated with a higher prostate cancer risk: a longitudinal, nested case-control study in the Nordic countries. Int. J. Cancer 108, 104-108 (2004).
8. Cross HS, Peterlik M, Reddy GS, Schuster I: Vitamin D metabolism in human colon adenocarcinoma-derived Caco-2 cells: expression of 25-hydroxyvitamin D3-1 á- hydroxylase activity and regulation of sidechain metabolism. J. Steroid Biochem. Mol. Biol. 62, 21-28 (1997).
9. Schwartz GG, Whitlatch LW, Chen TC, Lokeshwar BL, Holick MF: Human prostate cells synthesize 1,25-dihydroxyvitamin D3 from 25-hydroxyvitamin D3. Cancer Epidemiol. Biomarkers Prev. 7, 391-395 (1998).
10. Zehnder D, Bland R, Williams MC et al.: Extrarenal expression of 25-hydroxyvitamin D(3)-1 á-hydroxylase. J. Clin. Endocrinol. Metab. 86, 888-894 (2001).
11. Cross HS, Bareis P, Hofer H et al.: 25- Hydroxyvitamin D(3)-1á-hydroxylase and vitamin D receptor gene expression in human colonic mucosa is elevated during early cancerogenesis. Steroids 66, 287-292 (2001).
12. Kallay E, Bareis P, Bajna E et al.: Vitamin D receptor activity and prevention of colonichyperproliferation and oxidative stress. Food Chem. Toxicol. 40, 1191-1196 (2002).
13. Bises G, Kállay E, Weiland T et al.: 25- hydroxyvitamin D3-1 á -hydroxylase expression in normal and malignant human colon. J. Histochem. Cytochem. 52, 985-989 (2004).
14. Bareis P, Bises G, Bischof MG, Cross HS, Peterlik M: 25-hydroxyvitamin D metabolism in human colon cancer cells during tumor progression. Biochem. Biophys. Res. Commun. 285, 1012-1017 (2001).
15. Trump DL, Hershberger PA, Bernardi RJ et al. Anti-tumor activity of calcitriol: preclinical and clinical studies. J. Steroid Biochem. Mol. Biol. 90, 519-526 (2004).
16. Hsu JY, Feldman D, McNeal JE, Peehl DM: Reduced 1 á -hydroxylase activity in human prostate cancer cells correlates with decreased susceptibility to 25- hydroxyvitamin D3-induced growth inhibition. Cancer Res. 61, 2852-2856 (2001).
17. Ly LH, Zhao XY, Holloway L, Feldman D: Liarozole acts synergistically with 1 á,25- dihydroxyvitamin D3 to inhibit growth of DU 145 human prostate cancer cells by blocking 24-hydroxylase activity. Endocrinology 140, 2071-2076 (1999).
18. Cho E, Smith-Warner SA, Spiegelman D et al.: Dairy foods, calcium, and colorectal cancer: a pooled analysis of 10 cohort studies. J. Natl Cancer Inst. 96, 1015-1022 (2004).
19. Martinez ME, Marshall JR, Sampliner R, Wilkinson J, Alberts DS: Calcium, vitamin D, and risk of adenoma recurrence (United States). Cancer Causes Control 13, 213-220 (2002).
20. Lamprecht SA, Lipkin M: Chemoprevention of colon cancer by calcium, vitamin D and folate: molecular mechanisms. Nature Rev. Cancer 3, 601-614 (2003).
21. Kallay E, Bajna E, Wrba F et al. Dietary calcium and growth modulation of human colon cancer cells: role of the extracellular calcium-sensing receptor. Cancer Detect. Prev. 24, 127-136 (2000).
22. Sheinin Y, Kállay E, Wrba F et al.: Immunocytochemical localization of the extracellular calcium-sensing receptor in normal and malignant human large intestinal mucosa. J. Histochem. Cytochem. 48, 595-602 (2000).
23. Kallay E, Bonner E, Wrba F et al.: Molecular and functional characterization of the extracellular calcium-sensing receptor in human colon cancer cells. Oncol. Res. 13, 551-559 (2003).
24. Grau MV, Baron JA, Sandler RS et al.: Vitamin D, calcium supplementation, and colorectal adenomas: results of a randomized trial. J. Natl Cancer Inst. 95, 1765-1771 (2003).
25. Kallay E, SheininY, Peterlik M, Cross HS: Hormonal regulation of the expression of an extracellular calcium-sensing receptor in human colon cancer cells. Bone 22, 422 (1998).
26. Chan JM, Stampfer MJ, Ma J et al.: Dairy products, calcium, and prostate cancer risk in the Physicians Health Study. Am. J. Clin. Nutr. 74, 549-554 (2001).
27. Rodriguez C, McCullough M L, Mondul AM et al. Calcium, dairy products, and risk of prostate cancer in a prospective cohort of United States men. Cancer Epidemiol. Biomarkers Prev. 12, 597-603 (2003).
28. Young MV, Schwartz GG, Wang L et al.: The prostate 25-hydroxyvitamin D-1 á - hydroxylase is not influenced by parathyroid hormone and calcium: implications for prostate cancer chemoprevention by vitamin D. Carcinogenesis 25, 967-971 (2004).
29. Potter J, Bostick R, Grandits G et al.: Hormone replacement therapy is associated with lower risk of adenomatous polyps of the large bowel: the Minnesota Cancer Prevention Research Unit Case-Control Study. Cancer Epidemiol. Biomarkers Prev. 5, 779-784 (1996).
30. Campbell-Thompson M, Lynch IJ, Bhardwaj B: Expression of estrogen receptor (ER) subtypes and ER isoforms in colon cancer. Cancer Res. 61, 632-640 (2001).
31. Foley EF, Jazaeri AA, Shupnik MA, Jazaeri, O, Rice LW: Selective loss of estrogen receptor in malignant human colon. Cancer Res. 60, 245-248 (2000).
32. Cross HS, Kállay E, Lechner D et al.: Phytoestrogens and vitamin D metabolism: a new concept for the prevention and therapy of colorectal, prostate, and mammary carcinomas. J. Nutr. 134, 1207S-1212S (2004).
33. Kàllay E, Adlercreutz H, Farhan H et al. Phytoestrogens regulate vitamin D metabolism in the mouse colon: relevance for colon tumor prevention and therapy. J. Nutr. 132, 3490S-3493S (2002).
34. Ji Q, Liu PI, Elshimali Y, Stolz A: Frequent loss of estrogen and progesterone receptors in human prostatic tumors determined by quantitative real-time PCR. Mol. Cell. Endocrinol. 229, 103-110 (2005).
35. Lau KM, LaSpina M, Long J, Ho SM: Expression of estrogen receptor (ER)-á and ER- in normal and malignant prostatic epithelial cells: regulation by methylation and involvement in growth regulation. Cancer Res. 60, 3175-3182 (2000).
36. Brueggemeier RW, O'Reilly JM, Lovely CJ et al.: Effects of phytoestrogens and synthetic combinatorial libraries on aromatase, estrogen biosynthesis, and metabolism. Ann. NY Acad. Sci. 948, 51-66 (2001).
37. Farhan H, Wahala K, Cross HS: Genistein inhibits vitamin D hydroxylases CYP24 and CYP27B1 expression in prostate cells. J. Steroid Biochem. Mol. Biol. 84, 423-429 (2003).
38. Farhan H, Wahala K, Adlercreutz H, Cross HS: Isoflavonoids inhibit catabolism of vitamin D in prostate cancer cells. J. Chromatogr. B. Analyt. Technol. Biomed. Life Sci. 777, 261-268 (2002).
39. Greenwald P: Clinical trials in cancer prevention: current results and perspectives for the future. J. Nutr. 134, 3507S-3512S (2004).
40. Giovannucci E, Stampfer MJ, Colditz GA et al.: Multivitamin use, folate, and colon cancer in women in the Nurses Health Study. Ann. Intern. Med. 129, 517-524 (1998).
41. Weinstein SJ, Hartman TJ, Stolzenberg-Solomon R et al.: Null association between prostate cancer and serum folate, vitamin B(6), vitamin B(12), and homocysteine. Cancer Epidemiol. Biomarkers Prev. 12, 1271-1272 (2003).
42. Kim YI: Will mandatory folic acid fortification prevent or promote cancer? Am. J. Clin. Nutr. 80, 1123-1128 (2004).
43. Baylin SB, Herman JG, Graff JR., Vertino PM, Issa JP: Alterations in DNA methylation: a fundamental aspect of neoplasia. Adv. Cancer Res. 72, 141-196 (1998).
44. Bariol C, Suter C, Cheong K et al.: The relationship between hypomethylation and CpG island methylation in colorectal neoplasia. Am. J. Pathol. 162, 1361-1371 (2003).
45. Smirnoff P, Liel Y, Gnainsky J, Shany S, Schwartz B: The protective effect of estrogen against chemically induced murine colon carcinogenesis is associated with decreased CpG island methylation and increased mRNA and protein expression of the colonic vitamin D receptor. Oncol. Res. 11, 255-264 (1999).
46. Shi H, Yan PS, Chen CM et al.: Expressed CpG island sequence tag microarray for dual screening of DNA hypermethylation and gene silencing in cancer cells. Cancer Res. 62, 3214-3220 (2002).
47. Khorchide M, Lechner D, Cross HS: Epigenetic regulation of vitamin D hydroxylase expression and activity in normal and malignant human prostate cells. J. Steroid Biochem. Mol. Biol. 93(2-5), 167-172 (2005).
48. Albertson DG, Ylstra B, Segraves R: Quantitative mapping of amplicon structure by array CGH identifies CYP24 as a candidate oncogene. Nature Genet. 25, 144-146 (2000).